We recently reported that exposure of human cervical carcinoma cells to doxorubicin results in extracellular signal-regulated kinase (ERK)2 activation, which in turn phosphorylates p53 on a previously uncharacterized site, Thr55. This study sought to clarify the biological significance of doxorubicin-induced Thr55 phosphorylation. In breast carcinoma MCF7 cells, doxorubicin (300 nM) activated ERK2 and induced phosphorylation of p53 on Thr55 residues. Pretreatment of MCF7 cells with an ERK2 chemical inhibitor, PD98059 or U0126, blocked doxorubicin-induced p53 activation and suppressed phosphorylation of p53Thr55. MCF55a cells were established by transfection of full-length p53 carrying Thr55 mutation (Thr to Ala) into MCF7 cells. Doxorubicin (500 nM) could not induce p53 activation in MCF55a cells, which showed significantly increased drug resistance toward doxorubicin. While the expression of the apoptotic protein, Bax, showed no difference between MCF7 and MCF55a cells, Bcl-2, an antiapoptotic protein, was constitutively expressed in MCF55a cells. The increase of Bcl-2 protein and/or Bcl-2/Bax ratio might at least partly contribute to the drug resistance of MCF55a cells. In summary, our results suggest that phosphorylation of p53Thr55 by ERK2 is important for doxorubicin-induced p53 activation and cell death.
Introduction
The tumor suppressor p53 protein is a transcription factor involved in cell growth, differentiation and in the cellular response to various stresses (Bates and Vousden, 1996; Giaccia and Kastan, 1998) . It has been shown that p53 is commonly mutated in human tumors (Hollstein et al., 1991) . Loss of p53 function increases genomic instability and promotes tumor progression (Lane, 1992; Gottlieb and Oren, 1996; Ko and Prives, 1996) . P53 knockout mice eventually develop a wide spectrum of tumors (Donehower et al., 1992; Jacks et al., 1994) . Anticancer drugs kill tumors primarily via induction of apoptosis. Mutation of p53 may disrupt anticancer drug-induced apoptosis and probably results in drug resistance of tumor cells (Fan et al., 1995; Johnstone et al., 2002) .
Under normal physiological conditions, p53 is a short-lived protein. In response to DNA damage and other cellular stresses, p53 protein is stabilized and activated via post-transcriptional modifications, including phosphorylation, acetylation and sumoylation Liu et al., 1999; Meek, 1999; Rodriguez et al., 1999; Appella and Anderson, 2001) . Activated p53 affects its downstream genes either as a positive or a negative transactivating factor which directs cells primarily to growth arrest and/or apoptosis (Ryan et al., 2001; Sax and El-Deiry, 2003) . Kinases which have been reported to phosphorylate p53 include DNA-PK (Lees-Miller et al., 1992) , ATM (Banin et al., 1998; Canman et al., 1998) , ATR (Tibbetts et al., 1999) , p38 (Huang et al., 1999) , JNK (Milne et al., 1995; Bushmann et al., 2001) , ERK2 (Persons et al., 2000b; Yeh et al., 2001) , Chk1 (Shieh et al., 2000) , Chk2 (Hirao et al., 2000) , and CKI (Knippschild et al., 1997) . Numerous downstream genes of p53 have been identified by expression profiling analysis (Zhao et al., 2000; Kannan et al., 2001; Wang et al., 2001) , including genes involved in growth arrest (such as p21 CIP1 ), apoptosis (such as GADD45 and Bax), and auto-loop regulation of p53 (such as mdm2). How p53 converges various signals and activates downstream genes in a timely and orderly manner is largely unknown.
Reported phosphorylation sites of p53 include Ser6, 9, 15, 20, 33, 37, 46, and Thr18, 55 , and 81 at its Nterminus, and Ser-315 and 392 at its C-terminus (reviewed by Appella and Anderson, 2001) . Stressinduced phosphorylation of p53 leads to its stabilization and activation. For example, phosphorylation of Ser15 is thought to be necessary for p53 transcriptional activity (Banin et al., 1998; Canman et al., 1998) . Phosphorylation of Ser20 is involved in p53 tetramerization, transcriptional activity, and p53-induced apoptosis . In response to various stresses, p53 may be phosphorylated successively at different sites by different kinases to achieve optimal activity or to induce differential expression of downstream genes. However, how these p53 kinases are coordinated and which individual phosphorylated sites are involved in biological function have not been fully elucidated.
Extracellular signal-regulated kinase (ERK) is a subfamily of the mitogen-activated protein kinase (MAPK) family and is involved in various cellular responses (Marshall, 1998) . Most DNA damaging agents activate ERK in tumor cells (Tang et al., 2002) . However, the role of ERK activation in cellular response to DNA damaging agents is still unclear. Suppression of ERK2 activity was reported to sensitize ovarian carcinoma cells to cisplatin (Hayakawa et al., 1999; Persons et al., 2000b) , but also to induce drug resistance of cervical carcinoma cells to cisplatin (Wang et al., 2000; Yeh et al., 2002) . Recently, suppression of ERK has also been reported to increase drug resistance of various tumor cells to multiple anticancer drugs (Tang et al., 2002; Woessmann et al., 2002) .
We have reported that doxorubicin activates ERK2, which in turn physically interacts with and phosphorylates p53 at a previously uncharacterized site, Thr55 (Yeh et al., 2001) . However, the role of p53Thr55 phosphorylation in the function of p53 has not been fully characterized. This study sought to elucidate the biological significance of Thr55 phosphorylation by ERK2 in response to doxorubicin. Our results provide evidence that phosphorylation of p53Thr55 by ERK2 plays an important role in p53 activation, and that suppression of ERK2 or mutation of p53Thr55 may increase drug resistance of tumor cells.
Results

Doxorubicin induces p53 Thr55 phosphorylation and p53 activation
Whether doxorubicin activates p53 in MCF7 cells was determined by electromobility shift assay (EMSA) along the time course of treatment. As shown in Figure 1a , p53 was activated by 300 nM doxorubicin, peaking at 6-9 h and declining at 12 h post-treatment. The levels of p53 protein and phosphorylation of Thr55 were determined by Western blotting. As shown in Figure 1b , the level of p53 protein was increased by doxorubicin, and p53Thr55 was phosphorylated along a consistent time course of doxorubicin-induced p53 activation. The activation of ERK2 by doxorubicin was also determined by blotting with a phospho-ERK2-specific antibody. The time course of doxorubicin-induced ERK2 activation was similar with p53 activation and Thr55 phosphorylation.
Suppression of ERK2 activity by PD98059 inhibits doxorubicin-induced p53 activation
To characterize the biological significance of the interaction between ERK2 and p53 in response to doxorubicin, ERK2 activity was suppressed by the selective inhibitor, PD98059. As shown in Figure 2a , doxorubicin activated ERK2 in a dose-dependent manner, and pretreatment of cells with 20 mM PD98059 blocked doxorubicin-induced ERK2 activation. Next, the ability of doxorubicin, with or without PD98059, to activate p53 was examined by EMSA. As shown in Figure 2b (upper panel), doxorubicin activated p53 in a dose range similar to that necessary for ERK2 activation, and PD98059 suppressed this doxorubicininduced p53 activation. Suppression of ERK2 activity by another inhibitor, U0126, had a similar effect (Figure 2b , lower panel).
Suppression of ERK2 inhibits doxorubicin-induced p53 phosphorylation on Thr55 but not Ser15
The phosphorylation status of p53 following doxorubicin treatment was examined by Western blotting with anti-p53pThr55 and anti-p53pSer15 antibodies. Phosphorylation of Ser15 residue, a well-known event in response to DNA damage, was determined as a positive control and for comparison with Thr55. As shown in Figure 3a , doxorubicin-induced phosphorylation of p53 on both Thr55 and Ser15 residues. However, Figure 1 Time course analysis of doxorubicin-induced p53 activation, p53Thr55 phosphorylation and ERK2 activation. (a) MCF7 cells were treated with 300 nM doxorubicin for the indicated time intervals. Activation of p53 was characterized by EMSA. To confirm the identity of the p53-DNA complex (supershift experiment), anti-p53 antibody was added to nuclear extract prepared from cells treated with doxorubicin for 6 h. (b) MCF7 cells were treated with 300 nM for indicated time intervals. Nuclear extracts were prepared and subjected to Western blotting with antip53pThr55 and anti-pERK2 antibodies. The blots were reprobed with anti-p53 and anti-ERK2 antibodies, respectively pretreatment with U0126 only suppressed the phosphorylation on Thr55. The phosphorylation of p53 was further characterized by Western blotting of p53 immunoprecipitated complex with anti-p53pThr55 and anti-p53pSer15 antibodies. Consistent with the results of Western blotting, doxorubicin-induced p53 phosphorylation on both Ser15 and Thr55 residues, and PD98059 specifically inhibited Thr55 phosphorylation (Figure 3b ).
Expression of p53T55A protein does not affect cell growth but decreases chemosensitivity of MCF7 cells
To explore the functional significance of Thr55, a mutated p53 carrying Thr55 to Ala substitution was constructed in pIRES2-EGFP expression vector (pGFPp53T55A). MCF7 cells were transfected with pGFPp53T55A by Lipofectant. The transfectant cells (MCF55a) were selected by G418 and regularly verified by flow cytometry (data not shown). Western blotting showed an increased amount of p53 in MCF55a cells, indicating a constitutive expression of p53T55A ( Figure 4a ). The biological significance of Thr55 was elucidated by comparing the growth rate and chemosensitivity of MCF7 and MCF55a cells. As shown in Figure 4b , MCF55a had growth characteristics which were similar to parental cells, suggesting p53T55A did not affect cell proliferation. Next, the chemosensitivity to doxorubicin was compared between MCF7 and MCF55a cells. MTT assay revealed that MCF55a cells were more resistant to doxorubicin than parental MCF7 cells. Additionally, pretreatment of MCF7 cells with U0126 significantly increased the drug resistance to doxorubicin; by contrast, U0126 had little effect on MCF55a cells (Figure 4c ). The surviving curves of control vector-transfected cells (MCFGFP) to U0126 and doxorubicin were similar to that of the parental MCF7 cells (data not shown). To explore whether Thr55 is related to doxorubicin-induced apoptosis, the cell cycle distribution of MCF7 and MCF55a after 24 h treatment with 1 mM doxorubicin was determined by flow cytometry. As shown in Figure 4d , MCF7 cells had an increased sub-G1 fraction up to 12% after doxorubicin treatment. By contrast, MCF55a cells had no discernable sub-G1 fraction and were arrested in G2/M phases by doxorubicin.
Phosphorylation of Thr55 is not related to doxorubicininduced p53 stabilization but is necessary for doxorubicininduced p53 DNA-binding activity MCF7 and MCF55a cells were treated with various doses of doxorubicin for 6 h, and then the level of p53 protein was examined by Western blotting. As shown in Figure 5a (lower panel), doxorubicin increased p53 protein in both MCF7 and MCF55a cells, suggesting that p553Thr55 does not affect p53 stability. In addition, overexpression of p53T55A blocked the phosphorylation of endogenous p53Thr55 (Figure 5a , upper panel) but did not affect doxorubicin-induced phosphorylation on p53Ser15 (Figure 5b ). Whether doxorubicin induces p53 activation in MCF55a cells was examined by EMSA. As shown in Figure 5c , doxorubicin with or without PD98059 did not induce detectable p53 DNA-binding activity, indicating that Thr55 is the pivotal site of phosphorylation for p53 activation in response to doxorubicin, and overexpression of p53T55A suppressed the activity of endogenous p53. As a control, p53 was shown to be activated by doxorubicin and suppressed by PD98059 in MCFGFP cells (Figure 5d ). To further confirm phosphorylation of p53Thr55 is involved in p53 DNA-binding activity, supershift experiment was performed by using antip53pThr55 antibody. As shown in Figure 5e , antip53pThr55 antibody retarded the electromobility of p53-DNA complex.
Overexpression of p53T55A traps ERK2
As shown in Figure 5a , c, doxorubicin-induced phosphorylation of endogenous p53Thr55 and activation of endogenous p53 were suppressed in MCF55a cells. One possible explanation for this is that overexpression of To test this hypothesis, MCF7 and MCF55a cells were treated with 500 nM doxorubicin for 6 h, and the nuclear p53 was immunoprecipitated. After removing p53-coimmunoprecipitated complex, the nuclear lysates were further immunoprecipitated with anti-ERK2 antibody. All of the precipitated complexes were Western blotted with anti-ERK2 antibody. As shown in Figure 6 , doxorubicin increased p53-bound ERK2 fraction in MCF7 cells, but a relatively large amount of free ERK2 was still present. By contrast, p53 trapped almost all of the ERK2 in MCF55a cells. The interaction of p53 and ERK2 was further elucidated in a p53-null osteosarcoma cell line, Saos2. The Saos2 cells were transfected with pGFPp53T55A, and the transfected cells (Saos55A) were selected by the same strategy as MCF55a cells. As shown in Figure 7a , a constitutive expression of p53T55A was observed in Saos55A cells. Similarly, doxorubicin could not induce detectable p53 DNAbinding activity in Saos55a cells (Figure 7b ). Western blotting of p53-coimmunoprecipitated complex and post-p53, ERK2-coimmunoprecipitated complex with anti-ERK2 antibody showed a direct interaction between p53 and ERK2, and overexpressed p53 T55A trapped all ERK2, consistent with the results for MCF55a cells (Figure 7c ).
Phosphorylation of Thr55 has no effect on Bax but downregulates Bcl-2 expression
Since Bax is a well-defined p53 downstream gene and plays an important role in the cellular response to doxorubicin (Miyashita and Reed, 1995) , its expression was analysed in MCF7 and MCF55a cells by Western blotting. As shown in Figure 8 , a constitutive expression at similar levels of Bax was found in both MCF7 and MCF55a cells.
Bcl-2, a well-known antiapoptosis molecule (Hockenbery et al., 1990) , was reported to be downregulated by p53 (Haldar et al., 1994; Miyashita et al., 1994) . The protein level of Bcl-2 was found to play a critical role in Figure 6 P53 traps ERK2. MCF7 and MCF55a cells were treated with 500 nM doxorubicin for 6 h as indicated. Nuclear lysates were precipitated with anti-p53 antibody and protein A/G agarose successively. After removing p53-coimmunoprecipitated complex, the lysates were further immunoprecipitated with anti-ERK2 antibody. The complexes were resolved in 10% SDS-PAGE and transferred to nitrocellulose filter. The blot was Western blotted with anti-ERK2 antibody Figure 9a , doxorubicin alone induced little Bcl-2 protein, but pretreatment with PD98059 increased the protein level of Bcl-2 in MCF-7 cells. Further, a high constitutive expression of Bcl-2 was found in MCF55a cells, which was not affected by doxorubicin in the presence or absence of PD98059. For direct comparison, the cell lysates from various doses of doxorubicintreated MCF7 or MCF55a cells were run in parallel. A significantly higher level of Bcl-2 protein was observed in MCF55a cells. The role of p53Thr55 on the regulation of Bcl-2 expression was further characterized by RT-PCR. As shown in Figure 9b , Bcl-2 expression was induced in MCF7 cells 6 h after doxorubicin and PD98059 treatment, and returned to basal levels 24 h after treatment. By contrast, a constitutive expression of Bcl-2 was observed in MCF55a cells.
Discussion
Phosphorylation of p53 plays an important role in the cellular response to various stresses. Although multiple phosphorylation sites of p53 have been identified, the effect of the individual sites and the role of interaction among these sites in p53 functions have not been fully elucidated. In this study, we characterized the role of a novel site, Thr55, in response to doxorubicin. Our data demonstrate that doxorubicin activates ERK2 in breast carcinoma MCF7 cells, and the latter phosphorylates p53 on Thr55. Suppression of ERK2 or mutation of p53Thr55 blocks doxorubicin-induced p53Thr55 phosphorylation (Figure 3a, b) and p53 DNA-binding activity (Figure 2b ), indicating that Thr55 is the pivotal phosphorylation site for doxorubicin-induced p53 activation.
Genome-wide analysis has identified more than 150 genes which are positively or negatively regulated by p53 (Zhao et al., 2000; Kannan et al., 2001; Wang et al., 2001) . These genes are involved in growth arrest, DNA repair, apoptosis and feedback inhibition of p53. Little is known regarding how p53 differentially activates these downstream genes. It is possible that, after DNA damage or other types of cellular stresses, p53 is sequentially phosphorylated on different residues by different kinases. P53 with different sites or patterns of phosphorylation may have different effect on the downstream genes, and induce growth arrest or apoptosis. Enforced expression of p53T55A did not affect cell growth but increased drug resistance of transfected cells (Figure 4) , suggesting that p53Thr55 only plays a role in some selected p53 downstream pathways.
Certain residues of p53 may be phosphorylated earlier than others. ERK2 activity, which in this study was responsible for Thr55 phosphorylation, peaked at 6-9 h after doxorubicin treatment. By contrast, Ser15 phosphorylation occurs within a few minutes after DNA damage (Appella and Anderson, 2001 ). Therefore, phosphorylation of Ser15 is expected to occur before phosphorylation of Thr55. It is well known that phosphorylation of certain sites of p53 may affect the phosphorylation of others. For example, mutation of Ser33 and Ser46 affects Ser15 phosphorylation (Bulavin et al., 1999) . Whether Ser15 phosphorylation is necessary for Thr55 phosphorylation remains unclear, but our results suggest that phosphorylation of Thr55 has no effect on Ser15 phosphorylation, since suppression of ERK2 did not block Ser15 phosphorylation and doxorubicin-induced Ser15 phosphorylation of p53T55A. Thus, a sequential regulation of p53 activity might occur via a timely phosphorylation of p53 on different sites, resulting in differential activation of different downstream genes. It is also possible that different types of cellular stress in different cellular contexts may activate selected p53 downstream genes via phosphorylation of p53 at some specific sites.
Doxorubicin increased the protein level of p53 in both MCF7 and MCF55a cells, suggesting that Thr55 does not play a role in p53 stability (Figure 5a ). In p53-null osteosarcoma Saos2 cells, we also observed that doxorubicin prolonged the half-life of transfected p53T55A (data not shown). Tang et al. (2002) reported a similar observation that PD98059 has no effect on p53 stability. The stability of p53 may primarily be associated with Ser15 and Ser20 phosphorylation (Appella and Anderson, 2001 ). Indeed, doxorubicin-induced p53 phosphorylation on Ser15 residue in both MCF7 and MCF55a cells (Figures 3a, b and 5b) , and this p53Ser15 phosphorylation was not affected by suppression of ERK2 or mutation of p53Thr55.
In this study, we noted that expression of exogenous p53T55A interfered with DNA-binding activity of wildtype p53 in MCF55a cells. It is possible that transcriptionally active p53 needs tetramerization , and the resulting heteromers composed of wildtype p53 and p53T55A lose their DNA-binding ability. Another mechanism that may explain the suppression of endogenous wild-type p53 in MCF55a cells is that p53T55A traps ERK2, resulting in suppression of doxorubicin-induced phosphorylation of wild-type p53 on Thr55. This speculation was supported by the results of subtractive immunoprecipitation, which showed that overexpressed p53T55A trapped nearly all ERK2 (Figure 6 ). Similar results were observed in Saos55a cells (Figure 7) .
While doxorubicin induced a substantial increase of sub-G1 fraction in MCF7 cells, it induced no apoptosis but only G2/M block in MCF55a cells (Figure 4d ), suggesting that Thr55 mutation impairs the apoptotic machinery of MCF7 cells. It has been reported that intact p53 is required for the induction of apoptosis in cells that have been arrested in G2/M phases (Guillouf et al., 1995) .
A reciprocal inhibition between p53 and Bcl-2 has been previously reported. The expression of Bcl-2 is negatively regulated by p53 (Hockenbery et al., 1990; Haldar et al., 1994) . On the other hand, the balance of Bcl-2 and Bax may dictate the cellular response to DNA damaging agents (Reed, 1995) . In our study, while the expression of Bax was not affected by p53T55A, the amount of Bcl-2 was increased in both ERK2-suppressed MCF7 and p53T55A-overexpressing MCF55a cells. We also demonstrated that the increased Bcl-2 was primarily due to upregulated expression of Bcl-2 gene (Figure 9b ). Our data suggest that phosphorylation of p53Thr55 by ERK2 plays a major role in negative regulation of Bcl-2 expression. On the other hand, the increased Bcl-2 protein in MCF55a cells may at least partly contribute to increased drug resistance of these cells.
The role of ERK activity in the cellular response to DNA damaging agents appears to be cell context dependent. Persons et al. (2000b) reported that ERK increases p53 level in ovarian cells in response to cisplatin. Tang et al. (2002) showed that ERK mediates p53-independent cell cycle arrest and apoptosis. Woessmann et al. (2002) recently reported that ERK induces p53-independent cell death in osteosarcoma and neuroblastoma cells. Our study showed that phosphorylation of p53 on Thr55 by ERK2 plays a pivotal role in doxorubicin-induced cell death in MCF7 cells. The reasons for the discrepant findings among these studies are not clear, but might be related to different cell contexts, and different doses and schedules for treatment with cytotoxic agents.
In summary, this study demonstrated that ERK2 phosphorylates p53 at the Thr55 residue. Suppression of ERK2 or mutation of p53Thr55 results in blockage of p53 activity and consequently increases Bcl-2 expression, which may confer protection against apoptosis in breast carcinoma cells.
Materials and methods
Cell culture and chemicals
Human cervical carcinoma SiHa cells were cultured in DMEM supplemented with 10% fetal calf serum (FCS), and incubated in a humidified incubator with 5% CO 2 at 371C. MEK/ERK inhibitors, PD98059 and U0126, were purchased from Calbiochem, and other chemicals were obtained from Calbiochem or Sigma.
Electromobility shift assay
To determine the DNA-binding activity of p53, EMSA was performed as previously described (Yeh et al., 2001) . Briefly, the oligo-deoxynucleotide probe, 5 0 -GAACATGTCTAAG-CATGCTG, for p53 binding, was end-labeled with [ 32 P] by polynucleotide kinase. The 32 P-labeled probe was incubated with 10 mg nuclear extract in 15 ml reaction buffer (10 mM TrisHCl, pH 7.5, 1 mM EDTA, 75 mM KCl, 1 mM DTT, 4% Ficoll 400, 1 ug/ml salmon sperm DNA) at room temperature for 30 min, and then the electromobility of the probe was analysed in 5% native polyacrylamide gel.
Immunoblotting, reprobing and immunoprecipitation
Cells after various treatments were subjected to fractionation as previously described (Yeh et al., 2001) . Cytosolic and nuclear lysates were prepared and the protein concentration was determined using the Bio-Rad determination kit. Aliquots (15 mg) of lysates were subjected to immunoblotting. For reprobing, the membrane was washed with a stripping buffer (2% SDS, 7 ml b-mercaptoethanol in 100 ml TBS containing 0.2% Tween 20) for 30 min at room temperature, and then subjected to another blotting. Anti-p53pSer15 antibody was obtained from Cell Signaling Technology, Inc. All other antibodies used in this study were purchased from Santa Cruz Biotech. Aliquots (150 mg) of nuclear lysates were immunoprecipitated by anti-p53 antibody and protein-A/G agarose (Santa Cruz Biotechnology) as previously described (Yeh et al., 2001) . The immunocomplex was separated by 10% SDS-PAGE, and then immunoblotted with anti-p53pSer15, antip53pThr55 or anti-ERK2 antibody.
Site-directed mutagenesis and gene transfection
Site-directed mutagenesis of p53Thr55 was performed by a two-round PCR method as previously described (Yeh et al., 2001) . The PCR product was cloned into a bicistronic expression vector pIRES2-EGFP (Clontech). The mutation of Thr55 to Ala was confirmed by DNA sequencing. Purified plasmid was transfected into MCF7 and Saos2 cells with Lipofectant 2000 (Life Technologies, Inc.) according to the manufacturer's suggestions. MCF55a and Saos55a cells were selected by 500 mg/ml G418 for 20 days. The surviving colonies were pooled and cultured in medium containing 500 mg/ml G418 and routinely verified by FAScan.
Cytotoxicity assay
The cytotoxicity of doxorubicin was determined by a tetrazolium-based semiautomated colorimetric assay (MTT assay). Briefly, cells were seeded in a 96-well plate with 4000 cells/well. After overnight culture, cells were treated with various doses of doxorubicin and cultured for 3 days. The cell numbers were evaluated with an ELISA reader at OD 540 .
Analysis of cell proliferation
To determine the rate of cell growth, cells were seeded at 2 Â 10 3 cells/well in a 96-well plate. The medium was replaced every 72 h. The cell numbers were evaluated by MTT assay every 3 days.
Flow cytometric analysis
Cells were seeded at 2.0 Â 10 5 per 60 mm dish overnight. The cells were treated with 1 mM doxorubicin for 24 h, and then both floating and attached cells were collected. The cells were fixed with À201C methanol for at least 30 min and then stained with 50 mg/ml propidium iodide and 100 mg/ml RNase A for 30 min in the dark. The cell cycle distribution was determined by flow cytometric analysis (Becton Dickinson FACScan).
RT-PCR
Total RNAs were extracted from cells by various treatments with Trizol reagent (Life Technologies, Inc.) according to the manufacturer's instructions. For RT-PCR, the RNA (10 mg) was reverse transcribed into cDNA with random hexamer. Expression of gene was determined by PCR. The conditions of PCR were 951C 30 s, 551C 1 min and 721C 1 min for 30 cycles. The primers were 5 0 -AAGGATGGCGCACGCTC (forward) and 5 0 -TCACTTGTGGCTCAGATAGG (reverse) for Bcl-2, and 5 0 -TCGGAGTCAACGGATTTGG (forward) and 5 0 -GAATTTGCCATGGGTGGAAT (reverse) for GAPDH.
